ARC Regulatory, a global leader in research compliance for precision medicine clinical trials, is launching a new laboratory services division at its Belfast headquarters, supported by a 3-million-pound investment in a state-of-the-art facility. This expansion also includes a recruitment campaign to double its workforce from 25 to 50 and open a subsidiary office in Boston, further solidifying its global presence.

Located within the Catalyst innovation hub, ARC Regulatory has built a reputation for guiding life-changing therapies through complex regulatory pathways. The new lab, currently staffed by seven experts from the precision medicine sector, will enhance the company’s capabilities in assay validation, clinical trial sample testing, and in vitro diagnostic clinical studies.

Seamus Kearney, CEO and founder of ARC Regulatory has stated that, “The launch of our new laboratory services marks a transformative milestone in our mission to redefine regulatory support for precision medicine”. Kearney further added that, “By integrating cutting-edge laboratory capabilities with our existing regulatory and clinical operations expertise, we are providing clients with an unrivalled, end-to-end solution for global clinical trials”.

The CEO also emphasised that “This expansion enables us to offer seamless assay validation in compliance with international regulatory standards, manage regulatory submissions and approvals for the research and deliver the in vitro diagnostic clinical study in accordance with international good clinical practice guidelines”.

Seamus Kearney explained that Belfast was strategically chosen as the location for the lab, taking advantage of its state-of-the-art facilities and the exceptional talent pool of scientists from across the UK and Ireland. He added that the investment not only enhances ARC's service offerings but also strengthens Belfast’s role as a hub for research excellence in precision medicine.